FDA’s final guidance on using pathologic complete response as a surrogate endpoint in neoadjuvant breast cancer advocates running a single large study in the pre-operative setting, as opposed to the option for using two or more trials in different settings as laid out in the draft guidance.
FDA published draft guidance in May 2012 that outlined two different ways to get accelerated approval using the pCR endpoint...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?